Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
January 29, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics will unveil groundbreaking eight weeks’ gestation NIPT study results at the annual SMFM conference.
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
January 23, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics launches a new educational website providing information about reproductive and prenatal genetic testing called "Know More Sooner."
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
January 21, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced a hereditary cancer risk assessment program study was published in Obstetrics & Gynecology (also known as The Green Journal).
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
January 15, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics announces select preliminary fourth quarter and full year 2024 financial results and introduces full year 2025 financial guidance.
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
January 09, 2025 16:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced it signed an agreement with sports broadcaster Hannah Storm to promote the importance of knowing family cancer history.
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025 11:27 ET
|
Myriad Genetics, Inc.
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025 08:00 ET
|
Myriad Genetics, Inc.
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
January 07, 2025 08:00 ET
|
Myriad Genetics, Inc.
The University of Texas MD Anderson Cancer Center and Myriad Genetics announced a five-year strategic alliance.
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
January 06, 2025 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics released its Quality, Innovation, and Corporate Responsibility Report.
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
December 19, 2024 16:15 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.